Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Showed Reduction in Blood Glucose in Two Phase III Trials (NYSE:LLY)

RIDGEFIELD, Conn. and INDIANAPOLIS, June 15, 2014 /PRNewswire/ -- Two phase III clinical trials found  the investigational combination tablet of empagliflozin and linagliptin reduced blood glucose levels in adults with type 2 diabetes (T2D), Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) announced. The findings were presented as late breaking abstracts today at the American Diabetes Association 74th Scientific Sessions®. The 24-week primary findings of these two 52-week trials compared the combination of empagliflozin and linagliptin with empagliflozin or linagliptin alone in patients with T2D and moderately elevated blood glucose levels consistent with what is often seen in clinical practice.^1,2,3



Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Showed Reduction in Blood Glucose in Two Phase III Trials (NYSE:LLY)